본문 바로가기
KERD
논문KCI 등재

KASL clinical practice guidelines for management of chronic hepatitis B

The Korean Association for the Study of the Liver
대한간학회 (The korean Association for the Study of the Liver)|2022.04|Clinical and Molecular Hepatology|제28권 제2호|pp. 276-331

1

조회

0

다운로드

25

인용

0

참고문헌

키워드

TreatmentDisease managementTherapeuticsChronic hepatitis BKASL guidelines

참고문헌 (488)

  1. Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
  2. Hui CK, "Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase", Hepatology, 46, pp.395~401 (2007)
  3. Tran TT, "Immune tolerant hepatitis B: a clinical dilemma", Gastroenterol Hepatol (N Y), 7, pp.511~516 (2011)
  4. Chu CM, "Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels", Am J Med, 116, pp.829~834 (2004)
  5. Lee HA, "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase", Aliment Pharmacol Ther, 52, pp.196~204 (2020)
  6. Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)[DOI]
  7. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
  8. Chu CJ, "Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C", Gastroenterology, 122, pp.1756~1762 (2002)
  9. Livingston SE, "Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F", Gastroenterology, 133, pp.1452~1457 (2007)
  10. Tsai SL, "Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion", J Clin Invest, 89, pp.87~96 (1992)
  11. Lee PI, "Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children", Hepatology, 12(4 Pt 1), pp.657~660 (1990)
  12. Lok AS, "Acute exacerbations in Chinese patients with chronic hepatitis B virus(HBV)infection. Incidence, predisposing factors and etiology", J Hepatol, 10, pp.29~34 (1990)
  13. McMahon BJ, "The natural history of chronic hepatitis B virus infection", Hepatology, 49(5), pp.45~55 (2009)
  14. Hsu YS, "Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B", Hepatology, 35, pp.1522~1527 (2002)
  15. Bortolotti F, "Chronic hepatitis B in children after e antigen seroclearance : final report of a 29-year longitudinal study", Hepatology, 43, pp.556~562 (2006)
  16. Yim HJ, "Natural history of chronic hepatitis B virus infection : what we knew in 1981 and what we know in 2005", Hepatology (2006)
  17. Lok AS, "Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection", Gastroenterology, 92, pp.1839~1843 (1987)
  18. Sheen IS, "Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis", Gastroenterology, 89, pp.732~735 (1985)
  19. Martinot-Peignoux M, "Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers", J Hepatol, 36, pp.543~546 (2002)
  20. Zacharakis GH, "Natural history of chronic HBV infection : a cohort study with up to 12 years follow-up in North Greece(part of the Interreg I-II", EC-project), 2005, pp.77, 173~179
  21. de Franchis R, "The natural history of asymptomatic hepatitis B surface antigen carriers", Ann Intern Med, 118, pp.191~194 (1993)
  22. Fattovich G, "Natural history and prognosis of hepatitis B", Semin Liver Dis, 23, pp.47~58 (2003)
  23. Chen YC, "Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection", Gastroenterology, 123, pp.1084~1089 (2002)
  24. Lok AS, "Chronic hepatitis B : update 2009", Hepatology, 50, pp.661~662 (2009)
  25. Funk ML, "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants", J Viral Hepat, 9, pp.52~61 (2002)
  26. Lok AS, "Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal", Proc Natl Acad Sci U S A, 91, pp.4077~4081 (1994)
  27. Okamoto H, "Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen", J Virol, 68, pp.8102~8110 (1994)
  28. Tacke F, "Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants", J Virol, 78, pp.8524~8535 (2004)
  29. Croagh CM, "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B", Liver Int, 30, pp.1115~1122 (2010)
  30. Yoo BC, "Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea", J Hepatol, 38, pp.98~103 (2003)
  31. Raimondo G, "Statements from the Taormina expert meeting on occult hepatitis B virus infection", J Hepatol, 49, pp.652~657 (2008)
  32. Hoofnagle JH, "Management of hepatitis B : summary of a clinical research workshop", Hepatology, 45, pp.1056~1075 (2007)
  33. Hadziyannis SJ, "Hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 34(4 Pt 1), pp.617~624 (2001)
  34. Wu TT, "Clearance of hepatitis B surface antigen(HBsAg)after surgical resection of hepatocellular carcinoma", J Hepatol, 4, pp.45~51 (1987)
  35. Liaw YF, "Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection : a prospective study", Hepatology, 13, pp.627~631 (1991)
  36. Tout I, "Hepatitis B surface antigen seroclearance : immune mechanisms, clinical impact, importance for drug development", J Hepatol, 73, pp.409~422 (2020)
  37. Markus Cornberg, "Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference", Hepatology, 71(3), pp.1070~1092 (2020), Ovid Technologies (Wolters Kluwer Health)[DOI]
  38. Raimondo G, "Update of the statements on biology and clinical impact of occult hepatitis B virus infection", J Hepatol, 71, pp.397~408 (2019)
  39. Chu CM, "HBsAg seroclearance in asymptomatic carriers of high endemic areas : appreciably high rates during a long-term follow-up", Hepatology, 45, pp.1187~1192 (2007)
  40. Liu J, "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance : a community-based follow-up study", Gastroenterology, 139, pp.474~482 (2010)
  41. 남순우, "Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection", The Korean Journal of Internal Medicine, 22(2), pp.73~76 (2007), 대한내과학회
  42. Kim GA, "Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients : a need for surveillance", J Hepatol, 62, pp.1092~1099 (2015)
  43. Seto WK, "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B", Clin Microbiol Infect, 20, pp.1173~1180 (2014)
  44. Yip TC, "Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance", J Hepatol, 67, pp.902~908 (2017)
  45. Yip TC, "HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues", J Hepatol, 70, pp.361~370 (2019)
  46. Kim GA, "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B : clinical outcomes and durability", Gut, 63, pp.1325~1332 (2014)
  47. Choi J, "Comparison of long-term clinical outcomes between spontaneous and therapy-induced HBsAg seroclearance", Hepatology, 73, pp.2155~2166 (2021)
  48. Yip TC, "Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss", Aliment Pharmacol Ther, 53, pp.321~331 (2021)
  49. Park Y, "Risk and risk score performance of hepatocellular carcinoma development in patients with hepatitis B surface antigen seroclearance", Clin Transl Gastroenterol, 12, pp.e00290~ (2021)
  50. Di Bisceglie AM, "Determination of hepatitis B phenotype using biochemical and serological markers", J Viral Hepat, 24, pp.320~329 (2017)
  51. Hsu YN, "Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans", Dig Dis Sci, 59, pp.865~871 (2014)
  52. Yao K, "Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone", J Viral Hepat, 28, pp.1025~1033 (2021)
  53. Bonacci M, "Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone", Aliment Pharmacol Ther, 47, pp.1397~1408 (2018)
  54. Choi GH, "High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation", Aliment Pharmacol Ther, 50, pp.215~226 (2019)
  55. Hoang JK, "Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis", Medicine(Baltimore), 95, pp.e4433~ (2016)
  56. Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
  57. Teng W, "Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines", Hepatol Int, 15, pp.1421~1430 (2021)
  58. Lin SM, "Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection", Hepatology, 29, pp.971~975 (1999)
  59. Raffetti E, "Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B : a systematic review and meta-analysis", Liver Int, 36, pp.1239~1251 (2016)
  60. Lee KJ, "Natural history of chronic hepatitis type B throughout long-term follow-up", Korean J Gastroenterol, 29, pp.343~351 (1997)
  61. Liu S, "Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma : a meta-analysis", J Natl Cancer Inst, 101, pp.1066~1082 (2009)
  62. Yang HI, "Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.1134~1143 (2008)
  63. Tseng TC, "Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers", Gut, 64, pp.292~302 (2015)
  64. Jang JW, "Mutational complex genotype of the hepatitis B virus X", precore regions as a novel predictive marker for hepatocellular carcinoma, 2012, pp.103, 296~304
  65. Kim JK, "Specific mutations in the enhancer II", core promoter, J Med Virol, pp.2009, 81[DOI]
  66. Kao JH, "Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers", Gastroenterology, 124, pp.327~334 (2003)
  67. Wei F, "The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis", Medicine(Baltimore), 96, pp.e6835~ (2017)
  68. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  69. Fattovich G, "Hepatocellular carcinoma in cirrhosis : incidence and risk factors", Gastroenterology, 127(5), pp.35~50 (2004)
  70. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
  71. Bravi F, "Coffee and the risk of hepatocellular carcinoma and chronic liver disease : a systematic review and meta-analysis of prospective studies", Eur J Cancer Prev, 26, pp.368~377 (2017)
  72. Kennedy OJ, "Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma : a systematic review and dose-response meta-analysis", BMJ Open, 7, pp.e013739~ (2017)
  73. Petrick JL, "Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex : the liver cancer pooling project", Cancer Epidemiol Biomarkers Prev, 24, pp.1398~1406 (2015)
  74. Zhou YY, "Systematic review with network meta-analysis : antidiabetic medication and risk of hepatocellular carcinoma", Sci Rep, 6, pp.33743~ (2016)
  75. Hwang IC, "Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults", Sci Rep, 8, pp.4968~ (2018)
  76. Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment", Hepatology, 66, pp.1556~1569 (2017)
  77. Chen CI, "Cancer risk in HBV patients with statin and metformin use: a population-based cohort study", Medicine(Baltimore), 94, pp.e462~ (2015)
  78. Hsiang JC, "Statin and the risk of hepatocellular carcinoma and death in a hospitalbased hepatitis B-infected population : a propensity score landmark analysis", J Hepatol, 63, pp.1190~1197 (2015)
  79. Kim G, "Statin use and the risk of hepatocellular carcinoma in patients at high risk : a nationwide nested case-control study", J Hepatol, 68, pp.476~484 (2018)
  80. Pradelli D, "Statins and primary liver cancer : a meta-analysis of observational studies", Eur J Cancer Prev, 22, pp.229~234 (2013)
  81. Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
  82. Zhou YY, "Systematic review with network meta-analysis : statins and risk of hepatocellular carcinoma", Oncotarget, 7, pp.21753~21762 (2016)
  83. Goh MJ, "Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology, 71, pp.2023~2032 (2020)
  84. Choi WM, "Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B : a nationwide population-based study", Liver Int, 41, pp.2777~2785 (2021)
  85. Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
  86. Lee HW, "Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy", Am J Gastroenterol, 109, pp.1241~1249 (2014)
  87. Jung KS, "Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy", Hepatology, 62, pp.1757~1766 (2015)
  88. Papatheodoridis G, "PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy", J Hepatol, 64, pp.800~806 (2016)
  89. Kim MN, "Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir", Liver Int, 37, pp.1788~1795 (2017)
  90. Chon HY, "Addition of liver stiffness enhances the predictive accuracy of the PAGEB model for hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 53, pp.919~927 (2021)
  91. Kim JH, "Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy", J Hepatol, 69, pp.1066~1073 (2018)
  92. Lee HW, "External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy", Liver Int, 39, pp.1624~1630 (2019)
  93. Sharma SA, "Toronto HCC risk index : a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis", J Hepatol, 68, pp.92~99 (2018)
  94. Papatheodoridis GV, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B", J Hepatol, 72, pp.1088~1096 (2020)
  95. Ji JH, "External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals", J Viral Hepat, 28, pp.951~958 (2021)
  96. Chon HY, "Predictive performance of CAGE-B and SAGE-B models in Asian treatment-naive patients who started entecavir for chronic hepatitis B", Clin Gastroenterol Hepatol, 20, pp.e794~e807 (2022)
  97. Nam H, "Prediction of hepatocellular carcinoma by on-therapy response of noninvasive fibrosis markers in chronic hepatitis B", Am J Gastroenterol, 116, pp.1657~1666 (2021)
  98. Kim HY, "An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B", J Hepatol, 76, pp.311~318 (2022)
  99. Nam JY, "Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy", JHEP Rep, 2, pp.100175~ (2020)
  100. Si Hyun Bae, "Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea", Journal of Korean Medical Science, 20(5), pp.816~820 (2005), 대한의학회
  101. 조지현, "B형간염바이러스 유전자형의 국내 분포에 대한 연구", Clinical and Molecular Hepatology, 15(2), pp.140~147 (2009), 대한간학회
  102. Lin CL, "Natural history of acute and chronic hepatitis B : the role of HBV genotypes and mutants", Best Pract Res Clin Gastroenterol, 31, pp.249~255 (2017)
  103. Lin CL, "The clinical implications of hepatitis B virus genotype : recent advances", J Gastroenterol Hepatol, 26(Suppl 1), pp.123~130 (2011)
  104. Coffin CS, "New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection", Gastroenterology, 156, pp.355~368 (2019)
  105. Liu J, "Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression", Hepatology, 64, pp.381~389 (2016)
  106. Park H, "Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers", Liver Int, 32, pp.796~802 (2012)
  107. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
  108. Sonneveld MJ, "Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels", Hepatology, 58, pp.872~880 (2013)
  109. Chang ML, "Systematic review : cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B", Aliment Pharmacol Ther, 42, pp.243~257 (2015)
  110. 이한아, "Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B", Clinical and Molecular Hepatology, 22(3), pp.382~389 (2016), 대한간학회
  111. Wursthorn K, "Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients", Hepatology, 52, pp.1611~1620 (2010)
  112. Park Y, "Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory : two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay", Am J Clin Pathol, 137, pp.770~777 (2012)
  113. Mak LY, "Review article : hepatitis B core-related antigen(HBcrAg) : an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
  114. Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients", J Hepatol, 70, pp.615~625 (2019)
  115. Wong DK, "Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA", Liver Int, 37, pp.995~1001 (2017)
  116. Wang ML, "Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy", Clin Res Hepatol Gastroenterol, 43, pp.301~309 (2019)
  117. Drafting Committee for Hepatitis Management Guidelines, "Japan society of hepatology guidelines for the management of hepatitis B virus infection : 2019 update", Hepatol Res, 50, pp.892~923 (2020)
  118. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
  119. Carey I, "Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy", Hepatology, 72, pp.42~57 (2020)
  120. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
  121. Giersch K, "Serum HBV pgRNA as a clinical marker for cccDNA activity", J Hepatol, 66, pp.460~462 (2017)
  122. Seto WK, "Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation", Gut, 70, pp.775~783 (2021)
  123. Ghany MG, "Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in north America", Hepatology, 74, pp.2395~2409 (2021)
  124. Kaewdech A, "Hepatitis B surface antigen, core-related antigen and HBV RNA : predicting clinical relapse after NA therapy discontinuation", Liver Int, 40, pp.2961~2971 (2020)
  125. Liu S, "Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy", J Infect Dis (2021)
  126. Ding WB, "HBV", pregenomic RNA increases the stemness and promotes the development of HBV-related HCC through reciprocal regulation with insulin-like growth factor 2 mRNA-binding protein 3, 2021, pp.74, 1480~1495
  127. Allweiss L, "The role of cccDNA in HBV maintenance", Viruses, 9, pp.156~ (2017)
  128. Nassal M, "HBV cccDNA : viral persistence reservoir and key obstacle for a cure of chronic hepatitis B", Gut, 64, pp.1972~1984 (2015)
  129. Kumar R, "Clinical relevance of the study of hepatitis B virus covalently closed circular DNA", Liver Int, 36(Suppl 1), pp.72~77 (2016)
  130. Péneau C, "Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma", Gut, 71, pp.616~626 (2022)
  131. Jeong Won Jang, "Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance", Clinical and Molecular Hepatology, 27(1), pp.207~218 (2021), 대한간학회[DOI]
  132. Zhao LH, "Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma", Nat Commun, 7, pp.12992~ (2016)
  133. Sung WK, "Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma", Nat Genet, 44, pp.765~769 (2012)
  134. An J, "Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas", Hepatology, 75, pp.997~1011 (2022)
  135. Mendizabal M, "Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents", Clin Gastroenterol Hepatol, 18, pp.2554~2563 (2020)
  136. Zheng B, "The landscape of cell-free HBV integrations and mutations in cirrhosis and hepatocellular carcinoma patients", Clin Cancer Res, 27, pp.3772~3783 (2021)
  137. Tang LSY, "Chronic hepatitis B infection : a review", JAMA, 319, pp.1802~1813 (2018)
  138. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
  139. Xiao G, "Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection : a systemic review and meta-analysis", Hepatology, 61, pp.292~302 (2015)
  140. Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis", PLoS One, 7, pp.e44930~ (2012)
  141. Zhu X, "Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy", AST platelet ratio index and FIB-4 in patients with chronic HBV infection, 2011, pp.56, 2742~2749
  142. Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group", Hepatology, 24, pp.289~293 (1996)
  143. Andreani T, "Chronic hepatitis B virus carriers in the immunotolerant phase of infection : histologic findings and outcome", Clin Gastroenterol Hepatol, 5, pp.636~641 (2007)
  144. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
  145. Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회
  146. Lee HW, "Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals", Sci Rep, 9, pp.2508~ (2019)
  147. Mi Young Jeon, "Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(2), pp.295~304 (2021), 대한간학회[DOI]
  148. 신동현, "A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels", Gut and Liver, 11(4), pp.528~534 (2017), 거트앤리버 소화기연관학회협의회
  149. Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
  150. Park JY, "High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels", J Viral Hepat, 15, pp.615~621 (2008)
  151. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  152. Kim GA, "Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients", Aliment Pharmacol Ther, 51, pp.1169~1179 (2020)
  153. Shim JJ, "Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B : a large national cohort study", Liver Int, 38, pp.1751~1759 (2018)
  154. Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
  155. Wong VW, "Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients", J Clin Gastroenterol, 52, pp.347~352 (2018)
  156. Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus(HBV)e antigen-positive chronic HBV genotype C infection : a nationwide, multicenter, retrospective study", J Infect Dis, 216, pp.1407~1414 (2017)
  157. Kim HL, "Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B", Gut, 70, pp.2172~2182 (2021)
  158. Cho JY, "Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease", Gut, 63, pp.1943~1950 (2014)
  159. Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virusendemic population", Hepatology, 66, pp.1454~1463 (2017)
  160. Kwo PY, "ACG clinical guideline : evaluation of abnormal liver chemistries", Am J Gastroenterol, 112, pp.18~35 (2017)
  161. Lee JK, "Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology", Hepatology, 51, pp.1577~1583 (2010)
  162. Prati D, "Updated definitions of healthy ranges for serum alanine aminotransferase levels", Ann Intern Med, 137, pp.1~10 (2002)
  163. Won Gil Chung, "Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection", Clinical and Molecular Hepatology, 18(2), pp.195~202 (2012), 대한간학회
  164. Chao DT, "Systematic review with meta-analysis : the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU", L and significant hepatic fibrosis, 2014, pp.39, 349~358
  165. Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.1240~1248 (2011)[DOI]
  166. Yuen MF, "Prognostic determinants for chronic hepatitis B in Asians : therapeutic implications", Gut, 54, pp.1610~1614 (2005)
  167. Park HN, "Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease", Liver Int, 32, pp.937~944 (2012)
  168. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
  169. Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
  170. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
  171. Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
  172. Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B", N Engl J Med, 348, pp.800~807 (2003)
  173. Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B", N Engl J Med, 348, pp.808~816 (2003)
  174. Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
  175. undefined, "EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis", Journal of Hepatology, 63(1), pp.237~264 (2015), Elsevier BV[DOI]
  176. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
  177. 송병철, "Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?", Clinical and Molecular Hepatology, 20(4), pp.355~360 (2014), 대한간학회
  178. Kim HS, "Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 136, pp.505~512 (2009)
  179. Huang KW, "Efficacy and safety of lamivudine versus entecavir for treating chronic hepatitis B virus-related acute exacerbation and acute-on-chronic liver failure : a systematic review and meta-analysis", J Clin Gastroenterol, 51, pp.539~547 (2017)
  180. Tsai WL, "Chronic hepatitis B with spontaneous severe acute exacerbation", Int J Mol Sci, 16, pp.28126~28145 (2015)
  181. Chen CH, "Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants", J Hepatol, 41, pp.454~461 (2004)
  182. Kim KH, "Defining virologic relapse in chronic hepatitis B", Dig Dis Sci, 56, pp.2432~2438 (2011)
  183. Shih CA, "Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis", PLoS One, 10, pp.e0132426~ (2015)
  184. Garg H, "Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure", Hepatology, 53, pp.774~780 (2011)
  185. Wong VW, "Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B", J Hepatol, 54, pp.236~242 (2011)
  186. Tsai WL, "Early entecavir treatment for chronic hepatitis B with severe acute exacerbation", Antimicrob Agents Chemother, 58, pp.1918~1921 (2014)
  187. Jung Min Ha, "Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure", Clinical and Molecular Hepatology, 21(3), pp.232~241 (2015), 대한간학회
  188. Park JG, "Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B", Dig Liver Dis, 50, pp.163~167 (2018)
  189. Chen CH, "Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation", J Hepatol, 60, pp.1127~1134 (2014)
  190. Yasui S, "Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B", J Viral Hepat, 22, pp.94~102 (2015)
  191. Yue-Meng W, "The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure", Hepatol Int, 10, pp.462~469 (2016)
  192. Ahn JM, "Prediction of clinical outcomes in hepatitis B e antigen negative chronic hepatitis B patients with elevated hepatitis B virus DNA levels", PLoS One, 10, pp.e0144777~ (2015)
  193. Sinn DH, "The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria", J Viral Hepat, 26, pp.1465~1472 (2019)
  194. Paik N, "Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia", Liver Int, 38, pp.68~75 (2018)
  195. Cao Z, "A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha", Hepatology, 66, pp.1058~1066 (2017)
  196. de Niet A, "Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load : a randomised controlled, open-label trial", Lancet Gastroenterol Hepatol, 2, pp.576~584 (2017)
  197. Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
  198. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label followup study", Lancet, 381, pp.468~475 (2013)
  199. Chang TT, "Longterm entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
  200. 이정규, "Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels", Journal of Korean Medical Science, 30(11), pp.1618~1624 (2015), 대한의학회
  201. Kim JH, "Lowlevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment", Hepatology, 66, pp.335~343 (2017)
  202. Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
  203. Jang JW, "Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy", Clin Infect Dis, 71, pp.546~555 (2020)
  204. Cho YY, "Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients", J Viral Hepat, 25, pp.1161~1171 (2018)
  205. Lee HW, "Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA <2, 000 IU", mL, 2022, pp.117, 288~294
  206. Jang JW, "Longterm effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)
  207. Shim JH, "Efficacy of entecavir in treatment-naïve patients with hepatitis B virusrelated decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)
  208. Fontana RJ, "Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy", Gastroenterology, 123, pp.719~727 (2002)
  209. Perrillo R, "Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus", Gastroenterology, 109, pp.908~916 (1995)
  210. Marcellin P, "Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B", Gastroenterology, 150, pp.134~144 (2016)
  211. Lam AM, "Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus", Antimicrob Agents Chemother, 63, pp.e01734~ (2019)[DOI]
  212. Huang Q, "Preclinical profile and characterization of the hepatitis B virus core protein inhibitor ABI-H0731", Antimicrob Agents Chemother, 64, pp.e01463~ (2020)[DOI]
  213. Yuen MF, "Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection", Gastroenterology, 156, pp.1392~1403 (2019)
  214. Yuen MF, "Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor : a randomised, placebo-controlled phase 1 trial", Lancet Gastroenterol Hepatol, 5, pp.152~166 (2020)
  215. Zoulim F, "JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection", Gastroenterology, 159, pp.521~533 (2020)
  216. Yuen MF, "Antiviral activity and safety of the hepatitis B core inhibitor ABIH0731administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study", J Hepatol, 73, pp.S140~ (2020)
  217. Janssen H, "Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B : interim week 24 data", J Hepatol, 73, pp.S129~S130 (2020)
  218. Kang JA, "Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly", Nat Commun, 10, pp.2184~ (2019)
  219. Sun Woong Kim, "Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus", Clinical and Molecular Hepatology, 28(1), pp.17~30 (2022), 대한간학회[DOI]
  220. Ko C, "Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels", J Hepatol, 69, pp.1231~1241 (2018)
  221. Watts JK, "Silencing disease genes in the laboratory and the clinic", J Pathol, 226, pp.365~379 (2012)
  222. Gish RG, "Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent", Antiviral Res, 121, pp.97~108 (2015)
  223. Rex Wan-Hin Hui, "RNA interference as a novel treatment strategy for chronic hepatitis B infection", Clinical and Molecular Hepatology, 28(3), pp.408~424 (2022), 대한간학회[DOI]
  224. Yuen MF, "Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B : a phase 2randomized controlled trial", Nat Med, 27, pp.1725~1734 (2021)
  225. Gane E, "Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors", J Hepatol, 75, pp.S289~S290 (2021)
  226. Yuen MF, "Low HBsAg levels maintained following cessation of the GalNac-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy", Hepatology, 74, pp.1402A~1403A (2021)
  227. Yuen MF, "Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection", Hepatology, 74, pp.63A~ (2021)
  228. Yuen MF, "HBV RNAi inhibitor RG6346 in phase 1b-2a trial was safe, welltolerated, and resulted in substantial and durable reductions in serum HBsAg levels", American Association for the Study of Liver Diseases the Liver Meeting;, pp.13~16 (2020)
  229. Bazinet M, "Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy", Gastroenterology, 158, pp.2180~2194 (2020)
  230. Bazinet M, "Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus", hepatitis delta virus coinfection, 2021, pp.5, 189~202
  231. Gane E, "Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B : a phase 2 study", J Hepatol, 73, pp.S52~ (2020)
  232. Janssen HL, "Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis B", J Hepatol, 75, pp.S757~S758 (2021)
  233. Gane E, "Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B : a pilot study", J Hepatol, 71, pp.900~907 (2019)
  234. Wang G, "A phase IIa trial of subcutaneously administered PD-L1 antibody ASC22(envafolimab)in patients with chronic hepatitis B", Hepatology, 74, pp.62A~ (2021)
  235. Yoshida O, "Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP(CVP-NASVAC)in patients with chronic HBV infection : the results of 30 months follow up", Hepatology, 74, pp.64A~ (2021)
  236. Lok AS, "Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B", J Hepatol, 65, pp.509~516 (2016)
  237. Boni C, "Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis", Gastroenterology, 157, pp.227~241 (2019)
  238. Lee JH, "Entecavir plus pegylated interferon and sequential hepatitis B virus vaccination increases hepatitis B surface antigen seroclearance : a randomized controlled proof-of-concept study", Clin Infect Dis, 73, pp.e3308~e3316 (2021)
  239. Yuen MF, "First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B : JNJ-3989, JNJ-6379 and a nucleos(t)ide analogue", Hepatology, 70, pp.1489A~ (2019)
  240. Yuen MF, "Efficacy and safety of the siRNA JNJ-3989 and", or the capsid assembly modulator(CAM)JNJ-6379 for the treatment of chronic hepatitis B virus infection(CHB) : results from the phase 2B REEF-1 study, 2021, pp.74, 1390A~1391A
  241. Lee HW, "Hepatitis B core-related antigen : from virology to clinical application", Semin Liver Dis, 41, pp.182~190 (2021)
  242. Liu S, "Serum hepatitis B virus RNA : a new potential biomarker for chronic hepatitis B virus infection", Hepatology, 69, pp.1816~1827 (2019)
  243. Kao JH, "APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients", Hepatol Int, 15, pp.833~851 (2021)
  244. van Bömmel F, "Risks and benefits of discontinuation of nucleos(t)ide analogue treatment : a treatment concept for patients With HBeAg-negative chronic hepatitis B", Hepatol Commun, 5, pp.1632~1648 (2021)
  245. Liem KS, "Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B", Gastroenterology, 158, pp.1185~1190 (2020)
  246. Samuel Anthony Lachlan Hall, "Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis", Gut, pp.gutjnl~2020 (2021), BMJ[DOI]
  247. Jung KS, "Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients", J Gastroenterol, 51, pp.830~839 (2016)
  248. Song DS, "Improving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B", Clin Infect Dis, 73, pp.e892~e903 (2021)
  249. Kang SH, "Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients : a 10-year follow-up study", J Med Virol, 89, pp.849~856 (2017)
  250. Tout I, "Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B", Antiviral Res, 185, pp.104992~ (2021)
  251. Hyung Joon Yim, "Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop", Clinical and Molecular Hepatology, 26(4), pp.411~429 (2020), 대한간학회[DOI]
  252. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  253. Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
  254. Liaw YF, "Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C", Hepatology, 54, pp.1591~1599 (2011)
  255. Lampertico P, "Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B", Gut, 62, pp.290~298 (2013)
  256. Chon YE, "High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis", J Viral Hepat, 27, pp.1119~1126 (2020)
  257. Yang HC, "Viral factors affecting the clinical outcomes of chronic hepatitis B", J Infect Dis (2017)
  258. Mommeja-Marin H, "Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection : analysis and review of the literature", Hepatology, 37, pp.1309~1319 (2003)
  259. Chon YE, "Longterm effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B", J Gastroenterol Hepatol, 37, pp.200~207 (2022)
  260. Chon YE, "Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis", Am J Gastroenterol, 112, pp.882~891 (2017)
  261. Sung Won Lee, "Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(3), pp.402~412 (2021), 대한간학회[DOI]
  262. Kim WR, "Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Cancer, 121, pp.3631~3638 (2015)
  263. Liaw YF, "HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B", Hepatol Int, 3, pp.425~433 (2009)
  264. Xing T, "HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment : a systematic review and network meta-analysis", PLoS One, 12, pp.e0169444~ (2017)
  265. Papatheodoridis G, "Discontinuation of oral antivirals in chronic hepatitis B : a systematic review", Hepatology, 63, pp.1481~1492 (2016)
  266. Gara N, "Prospective study of withdrawal of antiviral therapy in patients with chronic hepatitis B after prolonged virological response", Hepatol Commun, 5, pp.1888~1900 (2021)
  267. Lee HW, "Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B", Hepatology, 51, pp.415~421 (2010)
  268. Chong CH, "When can we stop nucleoside analogues in patients with chronic hepatitis B?", Liver Int, 37(1), pp.52~58 (2017)
  269. Cornberg M, "The role of quantitative hepatitis B surface antigen revisited", J Hepatol, 66, pp.398~411 (2017)
  270. Liu J, "The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis B : a systematic review", Hepatology, 70, pp.1045~1055 (2019)
  271. Chen CH, "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment", J Hepatol, 61, pp.515~522 (2014)
  272. Wang CC, "Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg", Am J Gastroenterol, 111, pp.1286~1294 (2016)
  273. Jeng WJ, "Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 68, pp.425~434 (2018)
  274. Chen CH, "The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients", J Viral Hepat, 25, pp.590~597 (2018)
  275. Huang PY, "The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigennegative patients", J Viral Hepat, 28, pp.1141~1149 (2021)
  276. Hsu YC, "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk", Aliment Pharmacol Ther, 49, pp.107~115 (2019)
  277. Sonneveld MJ, "Prediction of Sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels : a multicenter study(CREATE)", Clin Gastroenterol Hepatol, 20, pp.e784~e793 (2022)
  278. Milan J. Sonneveld, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", Journal of Hepatology, 76(5), pp.1042~1050 (2022), Elsevier BV[DOI]
  279. Fan R, "Combining hepatitis B virus RNA and hepatitis B core-related antigen : guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B", J Infect Dis, 222, pp.611~618 (2020)
  280. Kim JH, "HBsAg seroclearance in chronic hepatitis B : implications for hepatocellular carcinoma", J Clin Gastroenterol, 45, pp.64~68 (2011)
  281. Yip TC, "Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients", J Hepatol, 68, pp.63~72 (2018)
  282. Kim MA, "Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance : a nationwide multicentre study", Gut, 69, pp.2214~2222 (2020)
  283. Margarita Papatheodoridi, "Risk of HBV reactivation during therapies for HCC: A systematic review", Hepatology, 75(5), pp.1257~1274 (2021), Ovid Technologies (Wolters Kluwer Health)[DOI]
  284. Kubo S, "Reactivation of viral replication after liver resection in patients infected with hepatitis B virus", Ann Surg, 233, pp.139~145 (2001)
  285. Dan JQ, "Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma : a retrospective study", Eur J Surg Oncol, 39, pp.865~872 (2013)
  286. Yoshida H, "Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma", Hepatol Int, 2, pp.89~94 (2008)
  287. Lee JI, "Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus", J Gastroenterol Hepatol, 29, pp.1019~1027 (2014)
  288. Xu M, "Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA : a propensity score matching analysis", World J Surg Oncol, 17, pp.45~ (2019)
  289. Sohn W, "Influence of hepatitis B virus reactivation on the recurrence of HBVrelated hepatocellular carcinoma after curative resection in patients with low viral load", J Viral Hepat, 22, pp.539~550 (2015)
  290. Jong-In Chang, "Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels", Digestive Diseases and Sciences, 67(9), pp.4565~4573 (2021), Springer Science and Business Media LLC[DOI]
  291. Wu CY, "Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection", JAMA, 308, pp.1906~1914 (2012)
  292. Yin J, "Effect of antiviral treatment with nucleotide", nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma : a two-stage longitudinal clinical study, 2013, pp.31, 3647~3655
  293. Huang G, "Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels : a randomized controlled trial", Ann Surg, 268, pp.943~954 (2018)
  294. Lee TY, "Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation", Hepatology, 63, pp.1517~1527 (2016)
  295. Wong JS, "Meta-analysis : the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 33, pp.1104~1112 (2011)
  296. Cho H, "Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals", J Viral Hepat, 25, pp.707~717 (2018)
  297. Choi J, "Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection", Hepatology, 73, pp.661~673 (2021)
  298. Tsai MC, "Tenofovir is superior to entecavir on recurrence in hepatitis B virus-related hepatocellular carcinoma after curative resection", J Gastroenterol Hepatol, 36, pp.163~ (2021)
  299. Lee JH, "The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma", Eur J Intern Med, 89, pp.48~55 (2021)
  300. Lao XM, "Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma", Liver Int, 33, pp.595~604 (2013)
  301. Lao XM, "Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma", Hepatol Res, 41, pp.553~563 (2011)
  302. Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", Hepatology, 43, pp.233~240 (2006)
  303. Park JW, "Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma : report of a prospective study", Am J Gastroenterol, 100, pp.2194~2200 (2005)
  304. Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
  305. Nagamatsu H, "Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy", Am J Gastroenterol, 99, pp.2369~2375 (2004)
  306. Tamori A, "Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma", Hepatol Res, 26, pp.77~80 (2003)
  307. Nagamatsu H, "Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC", Hepatol Res, 26, pp.293~301 (2003)
  308. Wang K, "Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative", Medicine(Baltimore), 97, pp.e10940~ (2018)
  309. Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 69, pp.813~819 (2007)
  310. Jun BG, "Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment : a multicenter study", PLoS One, 13, pp.e0201316~ (2018)
  311. Jang JW, "Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma", Antivir Ther, 16, pp.969~977 (2011)
  312. Jang JW, "Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma", PLoS One, 10, pp.e0122041~ (2015)
  313. Peng JW, "Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy", Asia Pac J Clin Oncol, 8, pp.356~361 (2012)
  314. Yang Y, "A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib", Liver Int, 35, pp.2147~2154 (2015)
  315. Lim S, "Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib", J Gastroenterol Hepatol, 30, pp.1024~1031 (2015)
  316. Loomba R, "Hepatitis B reactivation associated with immune suppressive and biological modifier therapies : current concepts, management strategies, and future directions", Gastroenterology, 152, pp.1297~1309 (2017)
  317. Yoo S, "Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment", Clin Gastroenterol Hepatol, 20, pp.898~907 (2022)
  318. Sun X, "Baseline HBV loads do not affect the prognosis of patients with hepatocellular carcinoma receiving anti-programmed cell death-1 immunotherapy", J Hepatocell Carcinoma, 7, pp.337~345 (2020)
  319. He MK, "Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis", Cancer Immunol Immunother, 70, pp.3207~3216 (2021)
  320. Buti M, "Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection", Dig Dis Sci, 60, pp.1457~1464 (2015)
  321. Lampertico P, "Review article : long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients", Aliment Pharmacol Ther, 44, pp.16~34 (2016)
  322. 이혜원, "Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)", Clinical and Molecular Hepatology, 22(4), pp.443~449 (2016), 대한간학회[DOI]
  323. Maggi P, "Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis : a longitudinal study", J Antimicrob Chemother, 70, pp.1150~1154 (2015)
  324. López-Alcorocho JM, "Prevalence of hepatitis B, hepatitis C, GB virus C", hepatitis G and TT viruses in predialysis and hemodialysis patients, 2001, pp.63, 103~107
  325. Gwak GY, "Occult hepatitis B virus infection in chronic hemodialysis patients in Korea", Hepatogastroenterology, 55, pp.1721~1724 (2008)
  326. Minuk GY, "Occult hepatitis B virus infection in a North American adult hemodialysis patient population", Hepatology, 40, pp.1072~1077 (2004)
  327. Burdick RA, "Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents : the DOPPS", Kidney Int, 63, pp.2222~2229 (2003)
  328. Johnson DW, "Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries : analysis of registry data", Nephrol Dial Transplant, 24, pp.1598~1603 (2009)
  329. Finelli L, "National surveillance of dialysis-associated diseases in the United States, 2002", Semin Dial, 18, pp.52~61 (2005)
  330. Agarwal K, "96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection", J Hepatol, 68, pp.672~681 (2018)
  331. Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
  332. Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
  333. Ahn SH, "Efficacy and safety of besifovir dipivoxil maleate compared With tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 17, pp.1850~1859 (2019)
  334. Chan HLY, "Maintenance of high levels of viral suppression and improved safety profile of tenofovir alafenamide(TAF)relative to tenofovir disoproxil fumarate(TDF)in chronic hepatitis B patients treated for 5 years in 2 ongoing phase 3 studies", American Associatio for the Study of Liver Diseases the Liver Meeting; (2020)
  335. Lampertico P, "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B : a randomised, double-blind, phase 3, multicentre non-inferiority study", Lancet Gastroenterol Hepatol, 5, pp.441~453 (2020)
  336. Byun KS, "Tenofovir alafenamide for drug-resistant hepatitis B : a randomized trial for switching from tenofovir disoproxil fumarate", Clin Gastroenterol Hepatol, 20, pp.427~437 (2022)
  337. Yim HJ, "Besifovir dipivoxil maleate 144-week treatment of chronic hepatitis B : an open-label extensional study of a phase 3 trial", Am J Gastroenterol, 115, pp.1217~1225 (2020)
  338. Do Seon Song, "Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial", Clinical and Molecular Hepatology, 27(2), pp.346~359 (2021), 대한간학회[DOI]
  339. Gupta S, "Spontaneous reactivation in chronic hepatitis B : patterns and natural history", J Clin Gastroenterol, 12, pp.562~568 (1990)
  340. Lok AS, "Chronic hepatitis B : update of recommendations", Hepatology, 39, pp.857~861 (2004)
  341. Tanaka Y, "Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus", Liver, 10, pp.6~10 (1990)
  342. Koo YX, "Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy", Cancer, 116, pp.115~121 (2010)
  343. Yeo W, "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy", Hepatology, 43, pp.209~220 (2006)
  344. Hwang JP, "Management of patients with hepatitis B who require immunosuppressive therapy", Nat Rev Gastroenterol Hepatol, 11, pp.209~219 (2014)
  345. Bessone F, "Management of hepatitis B reactivation in immunosuppressed patients : an update on current recommendations", World J Hepatol, 8, pp.385~394 (2016)
  346. Anna S.F. Lok, "Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study", Gastroenterology, 100(1), pp.182~188 (1991), Elsevier BV[DOI]
  347. Yeo W, "Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy : a prospective study of 626 patients with identification of risk factors", J Med Virol, 62, pp.299~307 (2000)
  348. Loomba R, "Systematic review : the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy", Ann Intern Med, 148, pp.519~528 (2008)
  349. Kwak LW, "Prognostic significance of actual dose intensity in diffuse large-cell lymphoma : results of a tree-structured survival analysis", J Clin Oncol, 8, pp.963~977 (1990)
  350. Bonadonna G, "Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer : the results of 20 years of follow-up", N Engl J Med, 332, pp.901~906 (1995)
  351. Yeo W, "Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy : a prospective study", J Med Virol, 70, pp.553~561 (2003)
  352. Jang JW, "Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy", World J Gastroenterol, 20, pp.7675~7685 (2014)
  353. Perrillo RP, "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy", Gastroenterology, 148, pp.221~244 (2015)
  354. K. Rajender Reddy, "American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy", Gastroenterology, 148(1), pp.215~219 (2015), Elsevier BV[DOI]
  355. Takai S, "Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy", Eur J Haematol, 74, pp.158~165 (2005)
  356. Hsu C, "A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma : a randomized trial", Hepatology, 47, pp.844~853 (2008)
  357. Engels EA, "Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea : a cohort study", Lancet Oncol, 11, pp.827~834 (2010)
  358. Cheng AL, "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma", Hepatology, 37, pp.1320~1328 (2003)
  359. Yeo W, "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab", J Clin Oncol, 27, pp.605~611 (2009)
  360. Dong HJ, "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis", J Clin Virol, 57, pp.209~214 (2013)
  361. Kim SJ, "Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group", Eur J Cancer, 49, pp.3486~3496 (2013)
  362. Tang Z, "Risk of hepatitis B reactivation in HBsAg-negative", HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma : a meta-analysis, 2017, pp.11, 429~433
  363. Hsu C, "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection : a prospective study", Hepatology, 59, pp.2092~2100 (2014)
  364. Chen XQ, "The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy", Med Oncol, 29, pp.1237~1241 (2012)
  365. Zurawska U, "Hepatitis B virus screening before chemotherapy for lymphoma : a cost-effectiveness analysis", J Clin Oncol, 30, pp.3167~3173 (2012)
  366. Buti M, "Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies : the Preblin study", PLoS One, 12, pp.e0184550~ (2017)
  367. Lau GK, "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation", Hepatology, 36, pp.702~709 (2002)
  368. Sarmati L, "Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper", Clin Microbiol Infect, 23, pp.935~940 (2017)
  369. Chen CY, "Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan", BMC Gastroenterol, 18, pp.6~ (2018)
  370. Chen FW, "Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease", Liver Int, 33, pp.1203~1210 (2013)
  371. Lee SK, "Reactivation of resolved hepatitis B after daratumumab for multiple myeloma", Clin Infect Dis, 73, pp.e1372~e1375 (2021)
  372. Kim S, "Hepatitis B virus X protein induces perinuclear mitochondrial clustering in microtubule-and dynein-dependent manners", J Virol, 81, pp.1714~1726 (2007)
  373. Dai MS, "Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration", Liver Int, 24, pp.540~546 (2004)
  374. Wu YT, "Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy : a systematic review and meta-analysis", PLoS One, 12, pp.e0179680~ (2017)
  375. Xu Z, "Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: a meta-analysis.", Eur J Cancer Care(Engl), 27, pp.e12799~ (2018)
  376. El-Sayed MH, "Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies", Hematol J, 4, pp.321~327 (2003)
  377. Yeo W, "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B santigen seropositive cancer patients undergoing cytotoxic chemotherapy", J Clin Oncol, 22, pp.927~934 (2004)
  378. Chung SJ, "Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy", J Rheumatol, 36, pp.2416~2420 (2009)
  379. Esteve M, "Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients : need for primary prophylaxis", Gut, 53, pp.1363~1365 (2004)
  380. Kim YJ, "Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases", J Rheumatol, 37, pp.346~350 (2010)
  381. Alameel T, "Risk of HBV reactivation among IBD patients with occult hepatitis B virus infection", Clin Gastroenterol Hepatol, 19, pp.621~622 (2021)
  382. Lee YH, "Hepatitis B virus reactivation in HBsAgpositive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs", Int J Rheum Dis, 16, pp.527~531 (2013)
  383. Roberto Pérez-Alvarez, "Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy", Medicine, 90(6), pp.359~371 (2011), Ovid Technologies (Wolters Kluwer Health)[DOI]
  384. Tzu-Chieh Lin, "Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis", Arthritis Care &amp; Research, 70(5), pp.724~731 (2018), Wiley[DOI]
  385. Burns EA, "Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors", J Immunother, 44, pp.132~139 (2021)
  386. Wang N, "Efficacy and safety of CAR19", 22 T-cell cocktail therapy in patients with refractory, Blood, pp.2020, 135[DOI]
  387. Lau GK, "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy", Gastroenterology, 125, pp.1742~1749 (2003)
  388. Saab S, "Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma : a decision analysis model", Hepatology, 46, pp.1049~1056 (2007)
  389. Viganò M, "Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders", Expert Opin Biol Ther, 16, pp.917~926 (2016)
  390. Hui CK, "Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy", Gut, 54, pp.1597~1603 (2005)
  391. Cerva C, "Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor", Clin Microbiol Infect, 22, pp.946~ (2016)
  392. Liu WP, "Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma", Leuk Lymphoma, 57, pp.1355~1362 (2016)
  393. Nakaya A, "Delayed HBV reactivation in rituximab-containing chemotherapy : how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?", Leuk Res, 50, pp.46~49 (2016)
  394. Paul S, "Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy : a meta-analysis", Hepatology, 66, pp.379~388 (2017)
  395. Cho Y, "High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma", J Med Virol, 88, pp.1010~1017 (2016)
  396. Rossi G, "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy", Br J Haematol, 115, pp.58~62 (2001)
  397. Li HR, "Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy", J Viral Hepat, 18, pp.877~883 (2011)
  398. Huang H, "Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy : a randomized clinical trial", JAMA, 312, pp.2521~2530 (2014)
  399. Yu S, "Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy : a meta-analysis", Int J Clin Pharm, 38, pp.1035~1043 (2016)
  400. Kim HY, "Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy : a multicenter study", J Med Virol, 90, pp.1593~1603 (2018)
  401. Inada K, "Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis", JGH Open, 5, pp.1085~1091 (2021)
  402. Lau GK, "High hepatitis B virus(HBV)DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation", Blood, 99, pp.2324~2330 (2002)
  403. Li J, "Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation", Tumour Biol, 34, pp.1723~1728 (2013)
  404. Huang H, "Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin’s lymphoma single institution experience", Expert Opin Pharmacother, 10, pp.2399~2406 (2009)
  405. Shang J, "A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients : a single-institutional experience", Bone Marrow Transplant, 51, pp.581~586 (2016)
  406. Siyahian A, "Prophylaxis for hepatitis B virus reactivation after allogeneic stem cell transplantation in the era of drug resistance and newer antivirals : a systematic review and meta-analysis", Biol Blood Marrow Transplant, 24, pp.1483~1489 (2018)
  407. Seto WK, "Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation : a prospective study", Hepatology, 65, pp.1451~1461 (2017)
  408. Park S, "Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus", Biol Blood Marrow Transplant, 17, pp.1630~1637 (2011)
  409. Yoo JJ, "Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation", Liver Int, 35, pp.2530~2536 (2015)
  410. Liu YC, "Hepatitis B virus infection in patients receiving allogeneic hematopoietic stem cell transplantation", J Pers Med, 11, pp.1108~ (2021)
  411. Hwang JP, "Hepatitis B virus screening for patients with cancer before therapy : American Society of Clinical Oncology provisional clinical opinion update", J Clin Oncol, 33, pp.2212~2220 (2015)
  412. Hwang JP, "Hepatitis B virus screening and management for patients with cancer prior to therapy : ASCO provisional clinical opinion update", J Clin Oncol, 38, pp.3698~3715 (2020)
  413. Lau G, "APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy", Hepatol Int, 15, pp.1031~1048 (2021)
  414. Lee HL, "Early hepatitis B surface antigen seroclearance following antiviral treatment in patients with reactivation of resolved hepatitis B", Dig Dis Sci, 64, pp.2992~3000 (2019)
  415. European Association for the Study of the Liver, "EASL clinical practice guidelines : liver transplantation", J Hepatol, 64, pp.433~485 (2016)
  416. Sripongpun P, "Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis", Clin Gastroenterol Hepatol, 18, pp.747~749 (2020)
  417. Rashidi-Alavijeh J, "Safety and efficacy of tenofovir alafenamide in liver transplant recipients : a single center experience", Transpl Infect Dis, 23, pp.e13522~ (2021)
  418. Wesdorp DJ, "Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective", J Clin Virol, 58, pp.67~73 (2013)
  419. Teperman LW, "Randomized trial of emtricitabine", tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation, 2013, pp.19, 594~601
  420. Stravitz RT, "Substitution of tenofovir", emtricitabine for hepatitis B immune globulin prevents recurrence of hepatitis B after liver transplantation, 2012, pp.32, 1138~1145
  421. Degertekin B, "Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation", Am J Transplant, 10, pp.1823~1833 (2010)
  422. Cholongitas E, "New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence", Transpl Int, 27, pp.1022~1028 (2014)
  423. Radhakrishnan K, "Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients", Transplantation, 101, pp.2079~2082 (2017)
  424. Manini MA, "Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients : a 5-year follow-up study after hepatitis B immunoglobulin withdrawal", Dig Liver Dis, 50, pp.944~953 (2018)
  425. Tanaka T, "The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation", Clin Transplant, 26, pp.E561~E569 (2012)
  426. Fung J, "Longterm outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation : results up to 8 years", Hepatology, 66, pp.1036~1044 (2017)
  427. Fung J, "Oral nucleoside", nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B, 2013, pp.108, 942~948
  428. Wang P, "Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis", PLoS One, 9, pp.e104480~ (2014)
  429. Miyaaki H, "Recurrent hepatitis B and D virus infection in a liver transplant recipient", Transplant Proc, 49, pp.175~177 (2017)
  430. Mederacke I, "Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation", J Hepatol, 56, pp.115~122 (2012)
  431. Cholongitas E, "Liver grafts from anti-hepatitis B core positive donors : a systematic review", J Hepatol, 52, pp.272~279 (2010)
  432. Skagen CL, "Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts-a systematic analysis", Clin Transplant, 25, pp.E243~E249 (2011)
  433. Perrillo R, "Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation : a survey of North American, European, and Asian-Pacific transplant programs", Liver Transpl, 15, pp.223~232 (2009)
  434. Huprikar S, "Solid organ transplantation from hepatitis B virus-positive donors : consensus guidelines for recipient management", Am J Transplant, 15, pp.1162~1172 (2015)
  435. Lee J, "Pretransplant hepatitis B viral infection increases risk of death after kidney transplantation:a multicenter cohort study in Korea", Medicine (Baltimore), 95, pp.e3671~ (2016)
  436. Thongprayoon C, "Outcomes of kidney transplantation in patients with hepatitis B virus infection : a systematic review and meta-analysis", World J Hepatol, 10, pp.337~346 (2018)
  437. Yap DY, "Entecavir treatment in kidney transplant recipients infected with hepatitis B", Clin Transplant, 28, pp.1010~1015 (2014)
  438. Hu TH, "A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients", Antivir Ther, 17, pp.745~753 (2012)
  439. Nho KW, "Kidney transplantation alone in end-stage renal disease patients with hepatitis B liver cirrhosis : a single-center experience", Transplantation, 99, pp.133~138 (2015)
  440. Veroux M, "Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and-negative recipients", Transplant Proc, 37, pp.2574~2575 (2005)
  441. Wachs ME, "The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-)organ donors", Transplantation, 59, pp.230~234 (1995)
  442. Fong TL, "Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation : analysis of united network of organ sharing database between 1994 and 1999", Transplantation, 73, pp.85~89 (2002)
  443. Jeon JW, "Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation", Transplantation, 102, pp.1717~1723 (2018)
  444. Lentine KL, "KDIGO clinical practice guideline on the evaluation and care of living kidney donors", Transplantation (2017)
  445. Duhart BT Jr, "Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation", Transpl Infect Dis, 5, pp.126~131 (2003)
  446. Blanpain C, "Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies : report on three cases and review of the literature", Transplantation, 66, pp.883~886 (1998)
  447. Knöll A, "Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen : low risk of HBV reactivation", Transplantation, 79, pp.1631~1633 (2005)
  448. Berger A, "HBV reactivation after kidney transplantation", J Clin Virol, 32, pp.162~165 (2005)
  449. Kanaan N, "Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection", J Clin Virol, 55, pp.233~238 (2012)
  450. Bae E, "Prevalence and clinical significance of occult hepatitis B virus infection among renal transplant recipients in Korea", Scand J Infect Dis, 44, pp.788~792 (2012)
  451. Nishimura K, "Clinical and virologic courses of hepatitis B surface antigen-negative and hepatitis B core or hepatitis B surface antibody-positive renal transplant recipients", Transplant Proc, 45, pp.1600~1602 (2013)
  452. Lee J, "Rituximab and hepatitis B reactivation in HBsAg-negative", anti-HBc-positive kidney transplant recipients, 2017, pp.32, 722~729
  453. Chen GD, "Outcomes and risk factors for hepatitis B virus(HBV)reactivation after kidney transplantation in occult HBV carriers", Transpl Infect Dis, 15, pp.300~305 (2013)
  454. 김유진, "Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus", Clinical and Molecular Hepatology, 17(3), pp.199~205 (2011), 대한간학회
  455. 최문석, "The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study", Gut and Liver, 6(2), pp.241~248 (2012), 거트앤리버 소화기연관학회협의회[DOI]
  456. Sagnelli E, "Influence of chronic coinfection with hepatitis B and C virus on liver histology", Infection, 32, pp.144~148 (2004)
  457. Lee LP, "Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients", J Gastroenterol Hepatol, 22, pp.515~517 (2007)
  458. Yang WT, "Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection", Medicine(Baltimore), 95, pp.e2995~ (2016)
  459. Pol S, "The negative impact of HBV", HCV coinfection on cirrhosis and its consequences, 2017, pp.46, 1054~1060
  460. Chen G, "Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents : a systematic review and meta-analysis", Hepatology, 66, pp.13~26 (2017)
  461. Yeh ML, "Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV", HCV co-infection, 2020, pp.73, 62~71
  462. Calvaruso V, "HBV reactivation in patients with HCV", HBV cirrhosis on treatment with direct-acting antivirals, 2018, pp.25, 72~79
  463. Bunnell KL, "Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection", Pharmacotherapy, 36, pp.e148~e153 (2016)
  464. Solas C, "Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients:impact on tenofovir trough concentrations and renal safety", Br J Clin Pharmacol, 84, pp.404~409 (2018)
  465. Mücke VT, "No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort", Aliment Pharmacol Ther, 46, pp.432~439 (2017)
  466. Tamori A, "Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy", J Viral Hepat, 25, pp.608~611 (2018)
  467. Sulkowski MS, "No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection", Clin Infect Dis, 63, pp.1202~1204 (2016)
  468. Urban S, "Hepatitis D virus in 2021 : virology, immunology and new treatment approaches for a difficult-to-treat disease", Gut, 70, pp.1782~1794 (2021)
  469. Stockdale AJ, "The global prevalence of hepatitis D virus infection : systematic review and meta-analysis", J Hepatol, 73, pp.523~532 (2020)
  470. Kim HS, "Prevalence and clinical significance of hepatitis D virus coinfection in patients with chronic hepatitis B in Korea", J Med Virol, 83, pp.1172~1177 (2011)
  471. 정숙향, "우리나라의 D형간염 바이러스 유병률과 임상 양상", Clinical and Molecular Hepatology, 11(2005), pp.43~50 (2005), 대한간학회
  472. Alfaiate D, "Chronic hepatitis D and hepatocellular carcinoma : a systematic review and meta-analysis of observational studies", J Hepatol, 73, pp.533~539 (2020)
  473. Bahcecioglu IH, "Prevalence of hepatitis delta virus(HDV)infection in chronic hepatitis B patients in eastern Turkey : still a serious problem to consider", J Viral Hepat, 18, pp.518~524 (2011)
  474. Fattovich G, "Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis(Eurohep)", Gut, 46, pp.420~426 (2000)
  475. Wedemeyer H, "Peginterferon plus adefovir versus either drug alone for hepatitis delta", N Engl J Med, 364, pp.322~331 (2011)
  476. Abbas Z, "Treatment of chronic hepatitis D patients with pegylated interferon : a real-world experience", Antivir Ther, 19, pp.463~468 (2014)
  477. Keskin O, "Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome", Clin Gastroenterol Hepatol, 13, pp.2342~2349 (2015)
  478. Heidrich B, "Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta", Hepatology, 60, pp.87~97 (2014)
  479. Triantos C, "Metaanalysis : antiviral treatment for hepatitis D", Aliment Pharmacol Ther, 35, pp.663~673 (2012)
  480. Karaca C, "Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response", Antivir Ther, 18, pp.561~566 (2013)
  481. Bogomolov P, "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B : first results of a phase Ib", IIa study, 2016, pp.65, 490~498
  482. Wedemeyer H, "Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta : 24 weeks interim data of the phase 3 MYR301 study", J Hepatol, 75, pp.S294~S295 (2021)
  483. Dhillon S, "Lonafarnib : first approval", Drugs, 81, pp.283~289 (2021)
  484. Cihan Yurdaydin, "A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis", Hepatology, 75(6), pp.1551~1565 (2021), Ovid Technologies (Wolters Kluwer Health)[DOI]
  485. Bazinet M, "Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection(REP 301 and REP 301-LTF) : a non-randomised, open-label, phase 2 trial", Lancet Gastroenterol Hepatol, 2, pp.877~889 (2017)
  486. Sandmann L, "Experimental drugs for the treatment of hepatitis D", J Exp Pharmacol, 13, pp.461~468 (2021)
  487. Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
  488. Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)

관련 논문AI추천

KASL clinical practice guidelines for management of chronic hepatitis BKorean Association for the Study of the Liver (KASL)대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제2호2025 KASL clinical practice guidelines for management of hepatitis CChang Hun Lee, Do Seon Song, Eun Ju Cho, Eun Sun Jang, Jae Hyun Yoon, Jae Seung Lee, Jae Yoon Jeong, Jung Gil Park, Nae-Yun Heo, Seul Ki Han, Young Kul Jung대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stopDong Hyun Sinn, Eileen L. Yoon, Hana Park, Hyung Joon Yim, Hyun Woong Lee, Jeong-Hoon Lee, Ji Hoon Kim, Jung Hyun Kwon, Jun Yong Park, Sae Hwan Lee대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis CThe Korean Association for the Study of the Liver대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제3호Erratum to ‘KASL clinical practice guidelines for management of chronic hepatitis B’ [Clin Mol Hepatol 2022;28:276-331]The Korean Association for the Study of the Liver (KASL)대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver diseaseBeom Kyung Kim, Dae Won Jun, Eun Joo Lee, Eun Ju Cho, Han Ah Lee, Hee Yeon Kim, Jihyun An, Ji Won Han, Jung Hwan Yu, Mi Na Kim, Minjong Lee, Moon Young Kim, Sang Gyune Kim, Seung-seob Kim, Seung Up Kim, Young Eun Chon, Young-Joo Jin, YoungRok Choi, Yuri Cho, Yu Rim Shin대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호

이 간행물의 다른 논문 (18건)

The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfallsSung Won Lee, Hae Lim Leepp. 121-134Approaches to quantifying hepatitis B virus covalently closed circular DNAThomas Tu, Henrik Zhangpp. 135-149MAFLD enhances clinical practice for liver disease in the Asia-Pacific regionTakuji Torimura, Takumi Kawaguchi, Mohammed Eslam, Tsubasa Tsutsumi, Dan Nakano, Jacob Georgepp. 150-163Cost-effectiveness of chronic hepatitis C screening and treatment김도영, 이한길, 이혜원, 김범경, Jae Young Jang, Young Changpp. 164-173Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still openBo Hyun Kimpp. 174-176
원문 보기